Barclays PLC Cullinan Oncology, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Barclays PLC holds 248,614 shares of CGEM stock, worth $3.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

248,614

Previous 248,614 -0.0%

Holding current value

$3.05 Million

Previous $4.16 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$16.03 - $20.86 $822,339 - $1.07 Million	51,300 Added 26.0%	248,614 $4.16 Million
Q2 2024 Aug 14, 2024	BUY	$15.63 - $29.35 $2.46 Million - $4.61 Million	157,122 Added 390.93%	197,314 $3.44 Million
Q1 2024 May 15, 2024	SELL	$10.17 - $19.02 $457,975 - $856,508	-45,032 Reduced 52.84%	40,192 $685,000
Q4 2023 Feb 15, 2024	BUY	$7.89 - $10.23 $251,146 - $325,631	31,831 Added 59.62%	85,224 $867,000
Q3 2023 Nov 07, 2023	BUY	$9.05 - $11.72 $286,432 - $370,938	31,650 Added 145.56%	53,393 $483,000
Q2 2023 Aug 03, 2023	SELL	$8.8 - $13.4 $57,816 - $88,038	-6,570 Reduced 23.2%	21,743 $232,000
Q1 2023 May 04, 2023	BUY	$10.2 - $11.91 $69,533 - $81,190	6,817 Added 31.71%	28,313 $291,000
Q4 2022 Feb 13, 2023	BUY	$9.72 - $13.62 $121,519 - $170,277	12,502 Added 139.0%	21,496 $227,000
Q3 2022 Nov 03, 2022	BUY	$11.82 - $15.42 $20,460 - $26,692	1,731 Added 23.83%	8,994 $116,000
Q2 2022 Aug 12, 2022	SELL	$7.31 - $13.55 $475 - $880	-65 Reduced 0.89%	7,263 $93,000
Q1 2022 May 16, 2022	BUY	$10.47 - $16.75 $76,724 - $122,744	7,328 New	7,328 $77,000

Others Institutions Holding CGEM

# of Institutions

146

Shares Held

67.6M

Call Options Held

612K

Put Options Held

118K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $560M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account